Avenue Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Note 4 - Related Party Agreements (Details Textual) - USD ($) $ in Millions		1 Months Ended	3 Months Ended
	Mar. 09, 2017	Feb. 28, 2015	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2022	Nov. 08, 2022
Fortress [Member]
Percentage of Fully-diluted Outstanding Equity		2.50%
Percentage of Equity or Debt Fnancing		2.50%
Stock Issued During Period, Shares, New Issues (in shares)			25,567	0
Fortress [Member] \| Avenue Baergic Founders Agreement [Member]
Excess in Net Assets Value	$ 100.0
Fortress [Member] \| Management Services Agreement [Member]
Costs and Expenses			$ 0.1	$ 0.1
Fortress [Member] \| Research and Development Expense [Member] \| Management Services Agreement [Member]
Service Provided, Expense Recorded, Percentage		50.00%
Fortress [Member] \| General and Administrative Expense [Member] \| Management Services Agreement [Member]
Service Provided, Expense Recorded, Percentage		50.00%
BaergicBio, Inc.[Member] \| Avenue Baergic Founders Agreement [Member]
Percentage of Equity Fee						2.50%
Percentage Of Additional Consideration Of Equity Fee					2.50%
Percentage Considered For The Calculation Of One-Time Fee					4.50%
Term of Agreement (Year)	5 years
Annual Consulting Fee	$ 0.5
Increase in Annual Consulting Fee	$ 1.0